Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru

Journal of Infectious Diseases

Volumn 174, Issue 2, 1996, Pages 268-275

  Lanata, Claudio F ^a   Midthun, Karen ^c   Black, Robert E ^c   Butron, Betzabe ^c   Huapaya, Ana ^c   Penny, Mary E ^c   Ventura, Gladis ^c   Gil, Ana ^c   Jett Goheen, Mary ^c   Davidson, Bruce L ^b  

^a INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOGLOBULIN A; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN ROTAVIRUS; IMMUNOGENICITY; INFANT; INFANTILE DIARRHEA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERU; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS TYPING; VOMITING;

EID: 8944236540     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.2.268     Document Type: Article

References (15)

1. Institute of Medicine. The prospects for immunizing against rotavirus. In: New vaccine development: establishing priorities. Diseases of importance in developing countries. Vol. II. Washington, DC: National Academy Press, 1986:308-18.
2. De Zoysa I, Feachem RG. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull WHO 1985;63:569-83.
3. Kapikian AZ, Flores J, Hoshino Y, et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination. J Infect Dis 1986;153:815-22.
4. Vesikari T, Isolauri E, d'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-81.
5. Vesikari T, Isolauri E, Delem A, et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985;107:189-94.
6. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine [letter]. Lancet 1986;2:108.
7. Hanlon P, Hanlon L, Marsh V, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;1:1342-5.
8. Lanata CF, Black RE, del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989;159:452-9.
9. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988;158:570-87.
10. Flores J, Perez-Schael I, Gonzalez M, et al. Protection against severe rotavirus diarrhea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987;1:882-4.
11. Perez-Schael I, Garcia D, Gonzalez M, et al. Prospective study of diarrheal disease in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 1990;30:219-29.
12. Christy C, Madore HP, Pichichero ME, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988;7:645-50.
13. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989;159:753-9.
14. Santosham M, Letson GW, Wolff M, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a native American population. J Infect Dis 1991;163:483-7.
15. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WC3 rotavirus and correlates of protection in healthy infants. J Infect Dis 1990;162:1055-62.